Monoclonal antibodies (mAbs) are currently the most investigated therapeutic compounds in oncology, but there is no monoclonal antibody approved in the treatment of multiple myeloma (MM). Nevertheless several really promising molecules are under investigation in phase III clinical trials. Dominantly daratumumab (anti-CD38) and elotuzumab (anti-CS1) showed extraordinary effectiveness in phase I/II trials. The toxicity was acceptable which is important for their addition to standard anti-myeloma agents like proteasome inhibitors or immunomodulatory drugs. Monoclonal antibodies such as denosumab (anti-RANKL) or BHQ880 (anti-DKK-1) are investigated also in the management of myeloma bone disease. This review is focused on the most promising mAbs, their mechanisms of action and the rationale of use. Practically all available results have been described. If the ongoing trials confirm the efficacy and safety of mAbs, they would become an important part of MM treatment that would be translated in the further improvement of therapeutic outcomes.

Department of Hematooncology University Hospital Ostrava 17 listopadu 1790 708 52 Ostrava Czech Republic; Faculty of Medicine University of Ostrava Syllabova 19 703 00 Ostrava Czech Republic

Citace poskytuje Crossref.org

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Natural Killer Cells in the Malignant Niche of Multiple Myeloma

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017

Current applications of multiparameter flow cytometry in plasma cell disorders

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future